The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI 822)/OBI 821 in the Adjuvant Treatment of Patients with High Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2021
This article has no abstract
Epistemonikos ID: 8019ad68f18fec9f0670af19da7abcbebcd50a45
First added on: Apr 12, 2025